Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

A next-generation treatment for breast cancer from Pfizer Inc. and Arvinas Inc. posted disappointing results in a final-stage ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...

Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after ...

Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...

Arvinas (NASDAQ:ARVN – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a research report issued on Tuesday, Marketbeat Ratings ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...